Metal cages placed in the setting of a heart attack can be life saving. In other settings, however, the strongest quality evidence says metal cages perform no better than medicines. One of the two* ...

DENVER -- As new 3- and 4-year data emerged from the ABSORB clinical trials, the FDA updated its cautions to healthcare professionals about continuing risk seen with the first-generation Absorb ...

SAN DIEGO -- The last of the new trials to report on the Absorb bioresorbable vascular scaffold (BVS) stent added certainty to the decision to halt sales of the first-generation device. The ABSORB IV ...

WASHINGTON, DC – A new study that compares the use of an everolimus-eluting bioresorbable vascular scaffold (BVS) with everolimus and biolimus eluting stents found that BVS demonstrated satisfactory ...

Please provide your email address to receive an email when new articles are posted on . A bioresorbable vascular scaffold treated patients with in-stent restenosis safely, but was not as effective as ...

First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic stents, which are currently the standard treatment for heart disease patients undergoing ...

Please provide your email address to receive an email when new articles are posted on . Vasomotion was more evident at 3 years in patients with STEMI who underwent primary PCI with a bioresorbable ...

CHICAGO.-- Northwestern's Bluhm Cardiovascular Institute recently enrolled its first subject in ABSORB III, a clinical trial to study a "disappearing" heart device for the treatment of coronary artery ...

WASHINGTON (March 18, 2017) -- Patients receiving the Absorb everolimus-eluting bioresorbable vascular scaffold (BVS), a dissolving stent to open clogged vessels around the heart, showed outcomes ...

The race for med-tech companies to get a bioabsorbable stent (BVS) on the U.S. market for coronary intervention procedures is quickly heating up. Abbott Vascular (Santa Clara, Calif.), a division of ...

WASHINGTON, DC — Patients who received the Absorb (Abbott Vascular) bioresorbable vascular scaffold (BVS) in the ABSORB-3 trial showed a primary outcome, counting only events occurring between the ...

SAN DIEGO — Results from two randomized controlled trials of a bioresorbable vascular scaffold (BVS) that has been withdrawn from the market call into question the wisdom of continued development of ...